SOUTH
SAN FRANCISCO, Calif., Nov. 29,
2024 /PRNewswire/ -- IDEAYA Biosciences, Inc.
(NASDAQ: IDYA), a precision medicine oncology company committed to
the discovery and development of targeted therapeutics, today
announced that, on November 27, 2024,
the Compensation Committee of IDEAYA's Board of Directors granted
non-qualified stock options to purchase an aggregate of 33,300
shares of the Company's common stock to a newly hired employee. The
stock options were granted under the IDEAYA Biosciences, Inc. 2023
Employment Inducement Incentive Award Plan (2023 Inducement Plan)
as an inducement material to such individual entering into
employment with IDEAYA in accordance with Nasdaq Listing Rule
5635(c)(4).
The 2023 Inducement Plan is used exclusively for the grant of
equity awards to individuals who were not previously employees of
IDEAYA, or following a bona fide period of non-employment, as an
inducement material to such individuals' entering into employment
with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of $26.99 per share, which is equal to the closing
price of IDEAYA's common stock on The Nasdaq Global Select Market
on the date of grant. The stock options have a 10-year term and
will vest over four years, with 25% of the options vesting on the
first anniversary of the vesting commencement date and the
remaining 75% of the options vesting in equal monthly installments
over the three years thereafter. Vesting of the stock options is
subject to such employee's continued service to IDEAYA on each
vesting date.
About IDEAYA Biosciences
IDEAYA is a precision
medicine oncology company committed to the discovery and
development of targeted therapeutics for patient populations
selected using molecular diagnostics. IDEAYA's approach
integrates capabilities in identifying and validating translational
biomarkers with drug discovery to select patient populations most
likely to benefit from its targeted therapies. IDEAYA is
applying its early research and drug discovery capabilities to
synthetic lethality – which represents an emerging class of
precision medicine targets.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302318041.html
SOURCE IDEAYA Biosciences, Inc.
